Literature DB >> 27212082

TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis.

Renee Rawson1, Tom Yang1, Robert O Newbury2, Melissa Aquino3, Ashmi Doshi1, Braxton Bell1, David H Broide3, Ranjan Dohil4, Richard Kurten5, Seema S Aceves6.   

Abstract

BACKGROUND: Eosinophilic esophagitis (EoE) is an allergic disease of increasing worldwide incidence. Complications are due to tissue remodeling and involve TGF-β1-mediated fibrosis. Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can be induced by TGF-β1, but its role in EoE is not known.
OBJECTIVE: We sought to understand the expression and role of PAI-1 in patients with EoE.
METHODS: We used esophageal biopsy specimens and plasma samples from control subjects and patients with EoE, primary human esophageal epithelial cells, and fibroblasts from patients with EoE in immunohistochemistry, quantitative PCR, and immunoassay experiments to understand the induction of PAI-1 by TGF-β1, the relationship between PAI-1 and esophageal fibrosis, and the role of PAI-1 in fibrotic gene expression.
RESULTS: PAI-1 expression was significantly increased in epithelial cells of biopsy specimens from patients with active EoE compared with that seen in biopsy specimens from patients with inactive EoE or control subjects (P < .001). Treatment of primary esophageal epithelial cells with recombinant TGF-β1 increased PAI-1 transcription, intracellular protein expression, and secretion. Esophageal PAI-1 expression correlated with basal zone hyperplasia, fibrosis, and markers of esophageal remodeling, including vimentin, TGF-β1, collagen I, fibronectin, and matrix metalloproteases, and plasma PAI-1 levels correlated with plasma TGF-β1 levels. PAI-1 inhibition significantly decreased baseline and TGF-β1-induced fibrotic gene expression.
CONCLUSIONS: PAI-1 expression is significantly increased in the epithelium in patients with EoE and reflects fibrosis, and its inhibition decreases TGF-β1-induced gene expression. Epithelial PAI-1 might serve as a marker of EoE severity and form part of a TGF-β1-induced profibrotic network.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eosinophil; SerpinE1; TGF-β1; esophagitis; fibrosis; remodeling

Mesh:

Substances:

Year:  2016        PMID: 27212082      PMCID: PMC5014565          DOI: 10.1016/j.jaci.2016.02.028

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  40 in total

1.  Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors:  Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

2.  Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis.

Authors:  Samer M A Abu-Sultaneh; Paul Durst; Virginia Maynard; Yoram Elitsur
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

Review 3.  Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.

Authors:  Seema S Aceves; Steven J Ackerman
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

4.  Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study.

Authors:  Alfredo J Lucendo; Angel Arias; Livia C De Rezende; Jose Luis Yagüe-Compadre; Teresa Mota-Huertas; Sonia González-Castillo; Rubén A Cuesta; José M Tenias; Teresa Bellón
Journal:  J Allergy Clin Immunol       Date:  2011-08-30       Impact factor: 10.793

5.  Cross-talk between human mast cells and bronchial epithelial cells in plasminogen activator inhibitor-1 production via transforming growth factor-β1.

Authors:  Seong H Cho; Sun H Lee; Atsushi Kato; Tetsuji Takabayashi; Marianna Kulka; Soon C Shin; Robert P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

6.  Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.

Authors:  Alain M Schoepfer; Ekaterina Safroneeva; Christian Bussmann; Tanja Kuchen; Susanne Portmann; Hans-Uwe Simon; Alex Straumann
Journal:  Gastroenterology       Date:  2013-08-13       Impact factor: 22.682

7.  Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.

Authors:  Wen-Tan Huang; Praveen K Vayalil; Toshio Miyata; James Hagood; Rui-Ming Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

8.  Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma.

Authors:  Seong Cho; Joseph Kang; Christopher Lyttle; Kathleen Harris; Brendan Daley; Leslie Grammer; Pedro Avila; Rajesh Kumar; Robert Schleimer
Journal:  Ann Allergy Asthma Immunol       Date:  2011-01-26       Impact factor: 6.347

Review 9.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

10.  PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model.

Authors:  Chad K Oh; Barbara Ariue; Rodrigo F Alban; Bryan Shaw; Seong H Cho
Journal:  Biochem Biophys Res Commun       Date:  2002-06-28       Impact factor: 3.575

View more
  25 in total

Review 1.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

2.  Interleukin 9 Alters Epithelial Barrier and E-cadherin in Eosinophilic Esophagitis.

Authors:  Ashmi Doshi; Rebecca Khamishon; Renee Rawson; Loan Duong; Lucas Dohil; Stephen J Myers; Braxton Bell; Ranjan Dohil; Robert O Newbury; Kim E Barrett; Richard C Kurten; Seema S Aceves
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-02       Impact factor: 2.839

3.  Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis.

Authors:  Mark Rochman; Jared Travers; Cora E Miracle; Mary C Bedard; Ting Wen; Nurit P Azouz; Julie M Caldwell; Kiran Kc; Joseph D Sherrill; Benjamin P Davis; Jeffrey K Rymer; Kenneth M Kaufman; Bruce J Aronow; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2017-01-17       Impact factor: 10.793

Review 4.  Pathophysiology of Eosinophilic Esophagitis.

Authors:  Kelly M O'Shea; Seema S Aceves; Evan S Dellon; Sandeep K Gupta; Jonathan M Spergel; Glenn T Furuta; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2017-07-27       Impact factor: 22.682

Review 5.  Epithelial origin of eosinophilic esophagitis.

Authors:  Mark Rochman; Nurit P Azouz; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2018-07       Impact factor: 10.793

6.  Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review.

Authors:  Brittany T Hines; Matthew A Rank; Benjamin L Wright; Lisa A Marks; John B Hagan; Alex Straumann; Matthew Greenhawt; Evan S Dellon
Journal:  Ann Allergy Asthma Immunol       Date:  2018-05-16       Impact factor: 6.347

Review 7.  Pathophysiology of Eosinophilic Esophagitis.

Authors:  Benjamin P Davis
Journal:  Clin Rev Allergy Immunol       Date:  2018-08       Impact factor: 8.667

8.  Conserved IFN Signature between Adult and Pediatric Eosinophilic Esophagitis.

Authors:  Melanie A Ruffner; Alex Hu; Julianna Dilollo; Kassidy Benocek; Donna Shows; Michael Gluck; Jonathan M Spergel; Steven F Ziegler; David A Hill; Karen Cerosaletti
Journal:  J Immunol       Date:  2021-02-08       Impact factor: 5.422

9.  Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis.

Authors:  Kelly A Whelan; Bridget C Godwin; Benjamin Wilkins; Okan U Elci; Alain Benitez; Maureen DeMarshall; Medha Sharma; Jonathan Gross; Andres J Klein-Szanto; Chris A Liacouras; Evan S Dellon; Jonathan M Spergel; Gary W Falk; Amanda B Muir; Hiroshi Nakagawa
Journal:  Clin Gastroenterol Hepatol       Date:  2019-09-06       Impact factor: 11.382

10.  Plasminogen Activator Inhibitor-1 as a Marker of Esophageal Functional Changes in Pediatric Eosinophilic Esophagitis.

Authors:  Prerana Williamson; James Proudfoot; Armen Gharibans; Lucas Dohil; Robert Newbury; Jacqueline Barsamian; Maheen Hassan; Renee Rawson; David Katzka; Richard Kurten; Ranjan Dohil; Hayat Mousa; Seema Aceves
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-30       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.